

# Profils cliniques évolutifs de la pemphigoïde bulleuse : étude rétrospective monocentrique de 312 cas

Élise Dandache

► **To cite this version:**

Élise Dandache. Profils cliniques évolutifs de la pemphigoïde bulleuse : étude rétrospective monocentrique de 312 cas. Médecine humaine et pathologie. 2018. dumas-02958092

**HAL Id: dumas-02958092**

**<https://dumas.ccsd.cnrs.fr/dumas-02958092>**

Submitted on 5 Oct 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



UNIVERSITE DE MONTPELLIER  
FACULTE DE MEDECINE MONTPELLIER-NIMES

**THESE**

Pour obtenir le titre de  
**DOCTEUR EN MEDECINE**

Présentée et soutenue publiquement

Par

**Elise DANDACHE**

Le 23 novembre 2018

**PROFILS CLINIQUES EVOLUTIFS DE LA  
PEMPHIGOÏDE BULLEUSE : ETUDE RETROSPECTIVE  
MONOCENTRIQUE DE 312 CAS**

Directeur de thèse : Pr Olivier DEREURE

JURY

Président : Pr Olivier DEREURE

Assesseurs : Pr Bernard GUILLOT

Dr Aurélie DU THANH

Dr Céline GIRARD

UNIVERSITE DE MONTPELLIER  
FACULTE DE MEDECINE MONTPELLIER-NIMES

**THESE**

Pour obtenir le titre de  
**DOCTEUR EN MEDECINE**

Présentée et soutenue publiquement

Par

**Elise DANDACHE**

Le 23 novembre 2018

**PROFILS CLINIQUES EVOLUTIFS DE LA  
PEMPHIGOÏDE BULLEUSE : ETUDE RETROSPECTIVE  
MONOCENTRIQUE DE 312 CAS**

Directeur de thèse : Pr Olivier DEREURE

JURY

Président : Pr Olivier DEREURE

Assesseurs : Pr Bernard GUILLOT

Dr Aurélie DU THANH

Dr Céline GIRARD

**ANNEE UNIVERSITAIRE 2017 - 2018**

**PERSONNEL ENSEIGNANT**

*Professeurs Honoraires*

ALLIEU Yves  
ALRIC Robert  
ARNAUD Bernard  
ASTRUC Jacques  
AUSSILLOUX Charles  
AVEROUS Michel  
AYRAL Guy  
BAILLAT Xavier  
BALDET Pierre  
BALDY-MOULINIER Michel  
BALMES Jean-Louis  
BALMES Pierre  
BANSARD Nicole  
BAYLET René  
BILLIARD Michel  
BLARD Jean-Marie  
BLAYAC Jean Pierre  
BLOTMAN Francis  
BONNEL François  
BOUDET Charles  
BOURGEOIS Jean-Marie  
BRUEL Jean Michel  
BUREAU Jean-Paul  
BRUNEL Michel  
CALLIS Albert  
CANAUD Bernard  
CASTELNAU Didier  
CHAPTAL Paul-André  
CIURANA Albert-Jean  
CLOT Jacques  
D'ATHIS Françoise  
DEMAILLE Jacques  
DESCOMPS Bernard

DIMEGLIO Alain  
DU CAILAR Jacques  
DUBOIS Jean Bernard  
DUMAS Robert  
DUMAZER Romain  
ECHENNE Bernard  
FABRE Serge  
FREREBEAU Philippe  
GALIFER René Benoît  
GODLEWSKI Guilhem  
GRASSET Daniel  
GROLLEAU-RAOUX Robert  
GUILHOU Jean-Jacques  
HERTAULT Jean  
HUMEAU Claude  
JAFFIOL Claude  
JANBON Charles  
JANBON François  
JARRY Daniel  
JOYEUX Henri  
LAFFARGUE François  
LALLEMANT Jean Gabriel  
LAMARQUE Jean-Louis  
LAPEYRIE Henri  
LESBROS Daniel  
LOPEZ François Michel  
LORiot Jean  
LOUBATIERES Marie Madeleine  
MAGNAN DE BORNIER Bernard  
MARY Henri  
MATHIEU-DAUDE Pierre

MEYNADIER Jean  
MICHEL François-Bernard  
MICHEL Henri  
MION Charles  
MION Henri  
MIRO Luis  
NAVARRO Maurice  
NAVRATIL Henri  
OTHONIEL Jacques  
PAGES Michel  
PEGURET Claude  
POUGET Régis  
PUECH Paul  
PUJOL Henri  
PUJOL Rémy  
RABISCHONG Pierre  
RAMUZ Michel  
RIEU Daniel  
RIOUX Jean-Antoine  
ROCHFORT Henri  
ROUANET DE VIGNE LAVIT Jean  
Pierre  
SAINT AUBERT Bernard  
SANCHO-GARNIER Hélène  
SANY Jacques  
SENAC Jean-Paul  
SERRE Arlette  
SIMON Lucien  
SOLASSOL Claude  
THEVENET André  
VIDAL Jacques  
VISIER Jean Pierre

*Professeurs Emérites*

ARTUS Jean-Claude  
BLANC François  
BOULENGER Jean-Philippe  
BOURREL Gérard  
BRINGER Jacques  
CLAUSTRES Mireille  
DAURES Jean-Pierre  
DAUZAT Michel  
DEDET Jean-Pierre  
ELEDJAM Jean-Jacques  
GUERRIER Bernard  
JOURDAN Jacques  
MAURY Michèle  
MILLAT Bertrand  
MARES Pierre  
MONNIER Louis  
PRAT Dominique  
PRATLONG Francine  
PREFAUT Christian

PUJOL Rémy  
ROSSI Michel  
SULTAN Charles  
TOUCHON Jacques  
VOISIN Michel  
ZANCA Michel

## Professeurs des Universités - Praticiens Hospitaliers

### *PU-PH de classe exceptionnelle*

ALBAT Bernard - Chirurgie thoracique et cardiovasculaire  
 ALRIC Pierre - Chirurgie vasculaire ; médecine vasculaire (option chirurgie vasculaire)  
 BACCINO Eric - Médecine légale et droit de la santé  
 BASTIEN Patrick - Parasitologie et mycologie  
 BONAFE Alain - Radiologie et imagerie médicale  
 CAPDEVILA Xavier - Anesthésiologie-réanimation  
 COMBE Bernard - Rhumatologie  
 COSTA Pierre - Urologie  
 COTTALORDA Jérôme - Chirurgie infantile  
 COUBES Philippe - Neurochirurgie  
 CRAMPETTE Louis - Oto-rhino-laryngologie  
 CRISTOL Jean Paul - Biochimie et biologie moléculaire  
 DAVY Jean Marc - Cardiologie  
 DE LA COUSSAYE Jean Emmanuel - Anesthésiologie-réanimation  
 DELAPORTE Eric - Maladies infectieuses ; maladies tropicales  
 DE WAZIERES Benoît - Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie  
 DOMERGUE Jacques - Chirurgie générale  
 DUFFAU Hugues - Neurochirurgie  
 DUJOLS Pierre - Biostatistiques, informatique médicale et technologies de la communication  
 ELIAOU Jean François - Immunologie  
 FABRE Jean Michel - Chirurgie générale  
 GUILLOT Bernard - Dermato-vénéréologie  
 HAMAMAH Samir-Biologie et Médecine du développement et de la reproduction ; gynécologie médicale  
 HEDON Bernard-Gynécologie-obstétrique ; gynécologie médicale  
 HERISSON Christian-Médecine physique et de réadaptation  
 JABER Samir-Anesthésiologie-réanimation  
 JEANDEL Claude-Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie  
 JONQUET Olivier-Réanimation ; médecine d'urgence  
 JORGENSEN Christian-Thérapeutique ; médecine d'urgence ; addictologie  
 KOTZKI Pierre Olivier-Biophysique et médecine nucléaire  
 LANDAIS Paul-Epidémiologie, Economie de la santé et Prévention  
 LARREY Dominique-Gastroentérologie ; hépatologie ; addictologie  
 LEFRANT Jean-Yves-Anesthésiologie-réanimation  
 LE QUELLEC Alain-Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie  
 MARTY-ANE Charles - Chirurgie thoracique et cardiovasculaire  
 MAUDELONDE Thierry - Biologie cellulaire  
 MERCIER Jacques - Physiologie  
 MESSNER Patrick - Cardiologie  
 MOURAD Georges-Néphrologie  
 PELISSIER Jacques-Médecine physique et de réadaptation  
 RENARD Eric-Endocrinologie, diabète et maladies métaboliques ; gynécologie médicale  
 REYNES Jacques-Maladies infectieuses, maladies tropicales  
 RIBSTEIN Jean-Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie  
 RIPART Jacques-Anesthésiologie-réanimation  
 ROUANET Philippe-Cancérologie ; radiothérapie  
 SCHVED Jean François-Hématologie; Transfusion  
 TAUREL Patrice-Radiologie et imagerie médicale  
 UZIEL Alain -Oto-rhino-laryngologie  
 VANDE PERRE Philippe-Bactériologie-virologie ; hygiène hospitalière  
 YCHOU Marc-Cancérologie ; radiothérapie

### **PU-PH de 1<sup>re</sup> classe**

AGUILAR MARTINEZ Patricia-Hématologie ; transfusion

AVIGNON Antoine-Nutrition  
 AZRIA David -Cancérologie ; radiothérapie  
 BAGHDADLI Amaria-Pédopsychiatrie ; addictologie  
 BEREGI Jean-Paul-Radiologie et imagerie médicale  
 BLAIN Hubert-Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie  
 BLANC Pierre-Gastroentérologie ; hépatologie ; addictologie  
 BORIE Frédéric-Chirurgie digestive  
 BOULOT Pierre-Gynécologie-obstétrique ; gynécologie médicale  
 CAMBONIE Gilles -Pédiatrie  
 CAMU William-Neurologie  
 CANOVAS François-Anatomie  
 CARTRON Guillaume-Hématologie ; transfusion  
 CHAMMAS Michel-Chirurgie orthopédique et traumatologique  
 COLSON Pascal-Anesthésiologie-réanimation  
 CORBEAU Pierre-Immunologie  
 COSTES Valérie-Anatomie et cytologie pathologiques  
 COURTET Philippe-Psychiatrie d'adultes ; addictologie  
 CYTEVAL Catherine-Radiologie et imagerie médicale  
 DADURE Christophe-Anesthésiologie-réanimation  
 DAUVILLIERS Yves-Physiologie  
 DE TAYRAC Renaud-Gynécologie-obstétrique, gynécologie médicale  
 DEMARIA Roland-Chirurgie thoracique et cardio-vasculaire  
 DEMOLY Pascal-Pneumologie ; addictologie  
 DEREURE Olivier-Dermatologie - vénéréologie  
 DROUPY Stéphane -Urologie  
 DUCROS Anne-Neurologie -  
 FRAPIER Jean-Marc-Chirurgie thoracique et cardiovasculaire  
 KLOUCHE Kada-Réanimation ; médecine d'urgence  
 KOENIG Michel-Génétique moléculaire  
 LABAUGE Pierre- Neurologie  
 LAFFONT Isabelle-Médecine physique et de réadaptation  
 LAVABRE-BERTRAND Thierry-Cytologie et histologie  
 LECLERCQ Florence-Cardiologie  
 LEHMANN Sylvain-Biochimie et biologie moléculaire  
 LUMBROSO Serge-Biochimie et Biologie moléculaire  
 MARIANO-GOULART Denis-Biophysique et médecine nucléaire  
 MATECKI Stéfan -Physiologie  
 MEUNIER Laurent-Dermato-vénéréologie  
 MONDAIN Michel-Oto-rhino-laryngologie  
 MORIN Denis-Pédiatrie  
 NAVARRO Francis-Chirurgie générale  
 PAGEAUX Georges-Philippe-Gastroentérologie ; hépatologie ; addictologie  
 PETIT Pierre-Pharmacologie fondamentale ; pharmacologie clinique ; addictologie  
 PERNEY Pascal-Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie  
 PUJOL Jean Louis-Pneumologie ; addictologie  
 PUJOL Pascal-Biologie cellulaire  
 PURPER-OUAKIL Diane-Pédopsychiatrie ; addictologie  
 QUERE Isabelle-Chirurgie vasculaire ; médecine vasculaire (option médecine vasculaire)  
 SOTTO Albert-Maladies infectieuses ; maladies tropicales  
 TOUITOU Isabelle-Génétique  
 TRAN Tu-Anh-Pédiatrie  
 VERNHET Hélène-Radiologie et imagerie médicale

#### **PU-PH de 2ème classe**

ASSENAT Éric-Gastroentérologie ; hépatologie ; addictologie  
 BERTHET Jean-Philippe-Chirurgie thoracique et cardiovasculaire  
 BOURDIN Arnaud-Pneumologie ; addictologie  
 CANAUD Ludovic-Chirurgie vasculaire ; Médecine Vasculaire

CAPDEVIELLE Delphine-Psychiatrie d'Adultes ; addictologie  
CAPTIER Guillaume-Anatomie  
CAYLA Guillaume-Cardiologie  
CHANQUES Gérald-Anesthésiologie-réanimation  
COLOMBO Pierre-Emmanuel-Cancérologie ; radiothérapie  
COSTALAT Vincent-Radiologie et imagerie médicale  
COULET Bertrand-Chirurgie orthopédique et traumatologique  
CUVILLON Philippe-Anesthésiologie-réanimation  
DAIEN Vincent-Ophtalmologie  
DE VOS John-Cytologie et histologie  
DORANDEU Anne-Médecine légale -  
DUPEYRON Arnaud-Médecine physique et de réadaptation  
FESLER Pierre-Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie  
GARREL Renaud -Oto-rhino-laryngologie  
GAUJOUX Viala Cécile-Rhumatologie  
GENEVIEVE David-Génétique  
GODREUIL Sylvain-Bactériologie-virologie ; hygiène hospitalière  
GUILLAUME Sébastien-Urgences et Post urgences psychiatriques -  
GUILPAIN Philippe-Médecine Interne, gériatrie et biologie du vieillissement; addictologie  
GUIU Boris-Radiologie et imagerie médicale  
HAYOT Maurice-Physiologie  
HOUEDE Nadine-Cancérologie ; radiothérapie  
JACOT William-Cancérologie ; Radiothérapie  
JUNG Boris-Réanimation ; médecine d'urgence  
KALFA Nicolas-Chirurgie infantile  
KOUYOUMDJIAN Pascal-Chirurgie orthopédique et traumatologique  
LACHAUD Laurence-Parasitologie et mycologie  
LALLEMANT Benjamin-Oto-rhino-laryngologie  
LAVIGNE Jean-Philippe-Bactériologie-virologie ; hygiène hospitalière  
LE MOING Vincent-Maladies infectieuses ; maladies tropicales  
LETOUZEY Vincent-Gynécologie-obstétrique ; gynécologie médicale  
LOPEZ CASTROMAN Jorge-Psychiatrie d'Adultes ; addictologie  
LUKAS Cédric-Rhumatologie  
MAURY Philippe-Chirurgie orthopédique et traumatologique  
MILLET Ingrid-Radiologie et imagerie médicale  
MORANNE Olivier-Néphrologie  
MOREL Jacques -Rhumatologie  
NAGOT Nicolas-Biostatistiques, informatique médicale et technologies de la communication  
NOCCA David-Chirurgie digestive  
PANARO Fabrizio-Chirurgie générale  
PARIS Françoise-Biologie et médecine du développement et de la reproduction ; gynécologie médicale  
PASQUIE Jean-Luc-Cardiologie  
PEREZ MARTIN Antonia-Physiologie  
POUDEROUX Philippe-Gastroentérologie ; hépatologie ; addictologie  
PRUDHOMME Michel-Anatomie  
RIGAU Valérie-Anatomie et cytologie pathologiques  
RIVIER François-Pédiatrie  
ROGER Pascal-Anatomie et cytologie pathologiques  
ROSSI Jean François-Hématologie ; transfusion  
ROUBILLE François-Cardiologie  
SEBBANE Mustapha-Anesthésiologie-réanimation  
SEGNARBIEUX François-Neurochirurgie  
SIRVENT Nicolas-Pédiatrie  
SOLASSOL Jérôme-Biologie cellulaire  
SULTAN Ariane-Nutrition  
THOUVENOT Éric-Neurologie  
THURET Rodolphe-Urologie  
VENAIL Frédéric-Oto-rhino-laryngologie  
VILLAIN Max-Ophtalmologie  
VINCENT Denis -Médecine interne ; gériatrie et biologie du vieillissement, médecine générale, addictologie

VINCENT Thierry-Immunologie  
 WOJTUSCISZYN Anne-Endocrinologie-diabétologie-nutrition

### **PROFESSEURS DES UNIVERSITES**

#### 1<sup>re</sup> classe :

COLINGE Jacques - Cancérologie, Signalisation cellulaire et systèmes complexes

#### 2<sup>ème</sup> classe :

LAOUDJ CHENIVESSE Dalila - Biochimie et biologie moléculaire

VISIER Laurent - Sociologie, démographie

### **PROFESSEURS DES UNIVERSITES - Médecine générale**

#### 1<sup>re</sup> classe :

LAMBERT Philippe

#### 2<sup>ème</sup> classe :

AMOUYAL Michel

### ***PROFESSEURS ASSOCIES - Médecine Générale***

DAVID Michel

RAMBAUD Jacques

### ***PROFESSEUR ASSOCIE - Médecine***

BESSIS Didier - Dermato-vénéréologie)

PERRIGAULT Pierre-François - Anesthésiologie-réanimation ; médecine d'urgence

ROUBERTIE Agathe – Pédiatrie

### **Maîtres de Conférences des Universités - Praticiens Hospitaliers**

#### **MCU-PH Hors classe**

CACHEUX-RATABOUL Valère-Génétique

CARRIERE Christian-Bactériologie-virologie ; hygiène hospitalière

CHARACHON Sylvie-Bactériologie-virologie ; hygiène hospitalière

FABBRO-PERAY Pascale-Epidémiologie, économie de la santé et prévention

HILLAIRE-BUYS Dominique-Pharmacologie fondamentale ; pharmacologie clinique ; addictologie

PELLESTOR Franck-Cytologie et histologie

PUJOL Joseph-Anatomie

RAMOS Jeanne-Anatomie et cytologie pathologiques

RICHARD Bruno-Thérapeutique ; addictologie

RISPAIL Philippe-Parasitologie et mycologie

SEGONDY Michel-Bactériologie-virologie ; hygiène hospitalière

STOEBNER Pierre -Dermato-vénéréologie

#### **MCU-PH de 1<sup>re</sup> classe**

ALLARDET-SERVENT Annick-Bactériologie-virologie ; hygiène hospitalière

BADIOU Stéphanie-Biochimie et biologie moléculaire

BOUDOUSQ Vincent-Biophysique et médecine nucléaire

BOULLE Nathalie-Biologie cellulaire

BOURGIER Céline-Cancérologie ; Radiothérapie

BRET Caroline -Hématologie biologique

COSSEE Mireille-Génétique Moléculaire

GABELLE DELOUSTAL Audrey-Neurologie

GIANSILY-BLAIZOT Muriel-Hématologie ; transfusion

GIRARDET-BESSIS Anne-Biochimie et biologie moléculaire

LAVIGNE Géraldine-Hématologie ; transfusion

LE QUINTREC Moglie-Néphrologie

MATHIEU Olivier-Pharmacologie fondamentale ; pharmacologie clinique ; addictologie

MENJOT de CHAMPFLEUR Nicolas-Neuroradiologie

MOUZAT Kévin-Biochimie et biologie moléculaire

PANABIERES Catherine-Biologie cellulaire



PHILIBERT Pascal-Biologie et médecine du développement et de la reproduction  
 RAVEL Christophe - Parasitologie et mycologie  
 SCHUSTER-BECK Iris-Physiologie  
 STERKERS Yvon-Parasitologie et mycologie  
 TUAILLON Edouard-Bactériologie-virologie ; hygiène hospitalière  
 YACHOUH Jacques-Chirurgie maxillo-faciale et stomatologie  
**MCU-PH de 2<sup>ème</sup> classe**  
 BERTRAND Martin-Anatomie  
 BRUN Michel-Bactériologie-virologie ; hygiène hospitalière  
 DU THANH Aurélie-Dermato-vénérologie  
 GALANAUD Jean Philippe-Médecine Vasculaire  
 GOUZI Farès-Physiologie  
 JEZIORSKI Éric-Pédiatrie  
 KUSTER Nils-Biochimie et biologie moléculaire  
 LESAGE François-Xavier-Médecine et Santé au Travail  
 MAKINSON Alain-Maladies infectieuses, Maladies tropicales  
 MURA Thibault-Biostatistiques, informatique médicale et technologies de la communication  
 OLIE Emilie-Psychiatrie d'adultes ; addictologie  
 THEVENIN-RENE Céline-Immunologie

#### **MAITRES DE CONFERENCES DES UNIVERSITES - Médecine Générale**

COSTA David  
 FOLCO-LOGNOS Béatrice

#### **MAITRES DE CONFERENCES ASSOCIES - Médecine Générale**

CLARY Bernard  
 GARCIA Marc  
 MILLION Elodie  
 PAVAGEAU Sylvain  
 REBOUL Marie-Catherine  
 SEGURET Pierre

#### **MAITRES DE CONFERENCES DES UNIVERSITES**

##### *Maîtres de Conférences hors classe*

BADIA Eric - Sciences biologiques fondamentales et cliniques

##### **Maîtres de Conférences de classe normale**

BECAMEL Carine - Neurosciences  
 BERNEX Florence - Physiologie  
 CHAUMONT-DUBEL Séverine - Sciences du médicament et des autres produits de santé  
 CHAZAL Nathalie - Biologie cellulaire  
 DELABY Constance - Biochimie et biologie moléculaire  
 GUGLIELMI Laurence - Sciences biologiques fondamentales et cliniques  
 HENRY Laurent - Sciences biologiques fondamentales et cliniques  
 LADRET Véronique - Mathématiques appliquées et applications des mathématiques  
 LAINE Sébastien - Sciences du Médicament et autres produits de santé  
 LE GALLIC Lionel - Sciences du médicament et autres produits de santé  
 LOZZA Catherine - Sciences physico-chimiques et technologies pharmaceutiques  
 MAIMOUN Laurent - Sciences physico-chimiques et ingénierie appliquée à la santé  
 MOREAUX Jérôme - Science biologiques, fondamentales et cliniques  
 MORITZ-GASSER Sylvie - Neurosciences  
 MOUTOT Gilles - Philosophie  
 PASSERIEUX Emilie - Physiologie  
 RAMIREZ Jean-Marie - Histologie  
 TAULAN Magali - Biologie Cellulaire

##### *PRATICIENS HOSPITALIERS UNIVERSITAIRES*

CLAIRE DAIEN-Rhumatologie

BASTIDE Sophie-Epidémiologie, économie de la santé et prévention

FAILLIE Jean-Luc-

Pharmacologie fondamentale ; pharmacologie clinique ; addictologie

GATINOIS Vincent-Histologie, embryologie et cytogénétique

HERLIN Christian -Chirurgie plastique ; reconstructrice et esthétique ; brûlologie

HERRERO Astrid-Chirurgie générale

PANTEL Alix-Bactériologie-virologie ; hygiène hospitalière

PERS Yves-Marie-Thérapeutique, médecine d'urgence ; addictologie

PINETON DE CHAMBRUN Guillaume-Gastroentérologie ; hépatologie ; addictologie

TORRE Antoine-Gynécologie-obstétrique ; gynécologie médicale

## REMERCIEMENTS

*A l'ensemble des membres du jury, qui m'ont fait l'honneur d'accepter cette fonction et de juger mon travail.*

### **A Monsieur le Professeur Olivier DEREURE**

*Je vous remercie de m'avoir proposé ce sujet très intéressant et d'avoir été mon directeur de thèse. Je vous remercie également pour votre perspicacité inaltérable, vos connaissances impressionnantes, votre bienveillance. Cela a été pour moi un honneur de travailler avec vous.*

### **A Monsieur le Professeur Bernard GUILLOT**

*Je vous remercie pour votre accompagnement et pour l'intérêt que vous portez à notre formation depuis le début de mon internat. Votre dévouement envers les patients, votre sens clinique et votre sérénité sont un modèle pour moi.*

### **A Madame le Docteur Aurélie DU THANH**

*Je te remercie pour tes compétences médicales étendues, rigoureuses et infaillibles ainsi que pour ta disponibilité et ta gentillesse. Les consultations à tes côtés sont toujours d'agréables moments, riches en apprentissage.*

### **A Madame le Docteur Céline GIRARD**

*Je te remercie de m'avoir aidée à aboutir à ce sujet de thèse. Tu as toujours été disponible et un modèle pour moi tant sur le plan humain que médical. Ta sympathie, ta polyvalence et ton aide précieuses m'ont énormément appris et apporté.*

*A tous les chefs qui ont contribué à ma formation tout au long de mon cursus :*

**A Mesdames et Messieurs Professeurs et Docteurs :**

*Pr Laurent MEUNIER, Pr Pierre STOEBNER, Pr Didier BESSIS, Dr Michel DANDURAND, Dr Candice LESAGE, Dr Bernadette OVTCHINNKOFF, Dr Myriam MARQUE, Dr Nadia RAISON-PEYRON, Dr Valérie PALLURE, Dr Jean-Luc BOURRAIN, Dr Luc DURAND, Dr Christophe DELFOUR*

Merci de tout ce que vous m'avez transmis durant ces 4 dernières années. J'espère avoir été digne de la confiance que vous m'avez accordée.

*A tout le personnel des services de Dermatologie des CHU de Montpellier et de Nîmes, d'Anatomopathologie du CHU de Montpellier, de Rhumatologie du CHU de Montpellier, de Médecine interne générale du CH de Perpignan*

*A mes chers collègues et anciens internes ou assistants : Agathe, Alexandre, Alicia, Aline, Alizée, Amandine, Annelies, Anne-Sophie, Anouck, Astrid, Aurélie C., Blanche, Camille, Chloé, Coline, Eleonore, Elsa, Emilie, Emma, Eric, Fawaz, Hugo, Julie, Justine, Laura, Léo-Paul, Louisa, Lucie, Marie D., Marie F, Marion B. et Marion B., Marion P., Mathilde, Mehdi, Melissa, Ondine, Quentin, Sarah, Séverin, Valentin, Valérie R., Vincent*

*A mes chers amis qui répondent toujours présent : Alice et Bastien, Camille, Claude et Chantal, Clémentine et Paul, Dorian, Marion et Julien, Nico, Pierrick, Sophie et Ben*

*A mes parents:* pour votre amour sans faille, vous m'avez porté tout au long de ma vie. J'espère pouvoir vous le rendre.

*A mon frère et à ma soeur, Jad et Célia :* unis pour la vie, merci pour tous ces moments passés ensemble et à venir. Que des souvenirs mémorables.

*Et à leur moitié, Laura et Julien*

*A Jesse,* pour ton soutien indéfectible. Tu me rends meilleure chaque jour. Ton humour, ton intelligence remplissent ma vie de bonheur et de surprises.

## SOMMAIRE

Liste des abréviations françaises

Contexte général

Article

“TIME-RELATED EVOLVING CLINICAL PATTERN OF  
BULLOUS PEMPHIGOID: A MONOCENTER RETROSPECTIVE  
SURVEY OF 312 CASES”

Abstract

Abbreviations and acronyms list

Introduction

Patients and Methods

Discussion

Conclusion

Tables

References

Serment

Permis d'imprimer

Abstract

## **LISTE DES ABREVIATIONS FRANCAISES**

BPAG1 bullous pemphigoid antigen 1

BPAG2 bullous pemphigoid antigen 2

ELISA Enzyme-Linked ImmunoSorbent Assay

IFD immunofluorescence directe

Ig immunoglobuline

JDE jonction dermo-épidermique

kD kiloDalton

PB Pemphigoïde Bulleuse

PDM pemphigoïde des muqueuses

PNE polynucléaire éosinophile

## CONTEXTE GENERAL

La pemphigoïde bulleuse (PB) est la maladie bulleuse auto-immune sous-épidermique la plus fréquente. La PB fait partie d'un groupe de 8 maladies bulleuses auto-immunes sous-épidermiques qui comprend également pemphigoïde gestationnelle, pemphigoïde des muqueuses (PDM), pemphigoïde des enfants, dermatite herpétiforme, dermatose à IgA linéaire, pemphigoïde anti-p200/laminin g1 et épidermolyse bulleuse acquise (1).

Dans la PB, les autoanticorps déposés à la jonction dermo-épidermique sont dirigés contre les héli-desmosomes et entraînent la formation d'une bulle sous-épidermique se développant au sein de la lamina lucida, dans la région supérieure de la membrane basale. Ces autoanticorps sont dirigés contre des protéines de structure des héli-desmosomes, principalement BPAg1 (protéine de 230kD) et BPAg2 (ou collagène XVII, protéine de 180 kD). Le domaine NC16a de l'ectodomaine de la protéine BP180, épitope proche du pôle basal des kératinocytes, a été identifié comme domaine immunodominant dans la PB et est différent de l'épitope-cible des autoanticorps anti-180kd des PDM avec autoanticorps anti-BPAg2 (2,3).

L'incidence dans le monde est estimée à 4,5 à 14 nouveaux cas par million d'habitants (4-9) et par an et en France à 21,7 nouveau cas par million d'habitants et par an, soit 3 fois supérieure à l'incidence estimée il y a 15 ans (10). Il n'y a pas de prédominance de sexe, d'ethnie ou géographique. Le taux de survie cumulée à 1 an est de 62% (10). Le risque de décès est 3 à 6 fois plus important que dans la population générale du même âge et de même sexe, plus en lien avec l'âge, l'état général du patient, les comorbidités neurologiques et les traitements spécifiques de la pemphigoïde bulleuse tels que la prise prolongée de corticostéroïdes systémiques qu'avec la sévérité de la maladie elle-même (10).

La PB est significativement associée à des affections neurologiques, principalement neurodégénératives mais également vasculaires. L'affection neurologique précède la PB dans 50 à 72% des cas, en moyenne 5,5 ans avant le diagnostic de PB. Le



lien physiopathologique entre BP et maladie neurologique n'est pas bien établi, peut-être par autoimmunité croisée vis-à-vis de l'antigène BPAG1 également présents dans le système nerveux central et démasquée par la maladie neurologique (11-14).

Cliniquement la PB se manifeste par un prurit souvent isolé au départ puis associé à une éruption bulleuse généralisée ou localisée accompagnée de lésions inflammatoires pseudo-urticariennes ou eczématiformes. La lésion élémentaire est une bulle reposant classiquement sur des plaques inflammatoires pseudo-urticariennes. Il existe des formes non-bulleuses où les symptômes sont un prurit isolé, à type de prurigo nodulaire, des plaques pseudo-urticariennes ou eczématiformes sans bulle, voire une érythrodermie. Contrairement à d'autres maladies bulleuses auto-immunes sous-épidermiques, les lésions cicatricielles sont classiquement absentes et la PB épargne la tête et cou ainsi que les muqueuses.

Le diagnostic de PB repose sur l'aspect clinique décrit ci-dessus, la présence d'une bulle sous épidermique avec un infiltrat dermique à PNE en histologie, la présence de dépôts linéaires d'IgG et/ou C3 à la jonction dermo-épidermique en IFD et la mise en évidence fréquente d'anticorps circulants anti BPAG1 et surtout anti BPAG2 par ELISA et Western Blot.

En 1998 le Groupe Bulle (Centre de référence national sur les maladies bulleuses auto-immunes) a proposé et validé un ensemble de 4 critères cliniques fortement associés au diagnostic de PB : âge supérieur à 70 ans, absence de cicatrices atrophiques, absence d'atteinte muqueuse, absence d'atteinte prédominante de la tête et du cou. Si au moins 3 critères sur 4 étaient présents, le diagnostic de PB pouvait être affirmé avec une sensibilité de 90%, une spécificité de 83% et une valeur prédictive positive de 95%. En 2004, le Groupe Bulle a confirmé la validité de ces critères clinique pour le diagnostic de PB en utilisant l'analyse du sérum des patients en immunoblot comme critère diagnostique principal, avec une sensibilité de 86%, une spécificité de 90% et une excellente valeur prédictive positive supérieure à 95%, si au moins 3 des 4 critères étaient présents, confirmant ainsi l'intérêt de cet ensemble de caractéristiques cliniques pour le diagnostic rapide de PB.

Cependant, le spectre clinique de la PB se modifie avec le temps et récemment un certain nombre de caractéristiques cliniques inhabituelles semblent émerger chez certains patients atteints de PB, notamment des atteintes palmo-plantaires prédominantes, des érosions extensives et une plus grande fréquence de lésions intra-buccales et de la tête et du cou. Cette étude monocentrique rétrospective portant sur une cohorte de grande taille de PB bien documentées a été menée pour mettre en évidence un changement possible des caractéristiques cliniques au cours du temps avec 2 objectifs principaux complémentaires : (i) décrire la fréquence des caractéristiques cliniques atypiques, dichotomisées en topographies atypiques et lésions cutanées élémentaires atypiques, et leur possible émergence au cours des 2 dernières décennies (ii) vérifier la validité au cours du temps des 4 critères cliniques diagnostiques mentionnés ci-dessus étant donné la possible augmentation de fréquence de caractéristiques cliniques atypiques.

## REFERENCES

1. Schmidt E, della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. *Immunol Allergy Clin North Am.* mai 2012;32(2):217-32, v.
2. Zillikens D, Mascaro JM, Rose PA, Liu Z, Ewing SM, Caux F, et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. *J Invest Dermatol.* nov 1997;109(5):679-83.
3. Di Zenzo G, Thoma-Uszynski S, Fontao L, Calabresi V, Hofmann SC, Hellmark T, et al. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. *Clin Immunol Orlando Fla.* sept 2008;128(3):415-26.
4. Bernard P, Vaillant L, Labeille B, Bedane C, Arbeille B, Denoeux JP, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. *Arch Dermatol.* janv 1995;131(1):48-52.
5. Increased risk of bullous pemphigoid in male and very old patients: A population-based study on incidence. - PubMed - NCBI [Internet]. [cité 24 juill 2018]. Disponible sur: <https://www.ncbi.nlm.nih.gov/pubmed/10426901>
6. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJP, West J. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. *BMJ.* 9 juill 2008;337:a180.
7. Gudi VS, White MI, Cruickshank N, Herriot R, Edwards SL, Nimmo F, et al. Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland. *Br J Dermatol.* août 2005;153(2):424-7.
8. Cozzani E, Parodi A, Rebora A, Delmonte S, Barile M, Nigro A, et al. Bullous pemphigoid in Liguria: a 2-year survey. *J Eur Acad Dermatol Venereol JEADV.* juill 2001;15(4):317-9.
9. Serwin AB, Bokinić E, Piascik M, Masny D, Chodynicka B. Epidemiological and clinical analysis of pemphigoid patients in northeastern Poland in 2000-2005. *Med Sci Monit Int Med J Exp Clin Res.* août 2007;13(8):CR360-364.
10. Joly P, Baricault S, Sparsa A, Bernard P, Bédane C, Duvert-Lehembre S, et al. Incidence and mortality of bullous pemphigoid in France. *J Invest Dermatol.* août 2012;132(8):1998-2004.
11. Lai YC, Yew YW, Lambert WC. Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol JEADV.* déc 2016;30(12):2007-15.
12. Cordel N, Chosidow O, Hellot M-F, Delaporte E, Lok C, Vaillant L, et al. Neurological disorders in patients with bullous pemphigoid. *Dermatol Basel Switz.* 2007;215(3):187-91.
13. Gambichler T, Segert H, Höxtermann S, Schmitz L, Altmeyer P, Teegen B. Neurological disorders in patients with bullous pemphigoid: clinical and experimental investigations. *J Eur Acad Dermatol Venereol JEADV.* sept 2015;29(9):1758-62.
14. Milani-Nejad N, Zhang M, Kaffenberger J. The association between bullous pemphigoid and neurological disorders: a systematic review. *Eur J Dermatol EJD.* 1 oct 2017;27(5):472-81.
15. de Quatrebarbes J, Joly P. [Bullous pemphigoid]. *Rev Prat.* 15 juin 2005;55(11):1165-8.
16. della Torre R, Combescure C, Cortés B, Marazza G, Beltraminelli H, Naldi L, et al. Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort. *Br J Dermatol.* nov 2012;167(5):1111-7.
17. Bakker CV, Terra JB, Pas HH, Jonkman MF. Bullous Pemphigoid as Pruritus in the Elderly: A Common Presentation. *JAMA Dermatol.* 1 août 2013;149(8):950-3.
18. Joly P, Courville P, Lok C, Bernard P, Saiag P, Dreno B, et al. Clinical criteria for the diagnosis of bullous pemphigoid: a reevaluation according to immunoblot analysis of patient sera. *Dermatol Basel Switz.* 2004;208(1):16-20.
19. Vaillant L, Bernard P, Joly P, Prost C, Labeille B, Bedane C, et al. Evaluation of clinical

criteria for diagnosis of bullous pemphigoid. French Bullous Study Group. *Arch Dermatol.* sept 1998;134(9):1075-80.

20. Esmaili N, Hallaji Z, Soori T, Chams Davatchi C. Bullous pemphigoid in Iranian patients: a descriptive study on 122 cases. *Acta Med Iran.* 2012;50(5):335-8.

21. Chang YT, Liu HN, Wong CK. Bullous pemphigoid--a report of 86 cases from Taiwan. *Clin Exp Dermatol.* janv 1996;21(1):20-2.

22. Kridin K, Bergman R. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients. *JAMA Dermatol* [Internet]. 8 août 2018 [cité 14 août 2018]; Disponible sur: <https://jamanetwork.com/journals/jamadermatology/fullarticle/2695085>

23. Di Zenzo G, Marazza G, Borradori L. Bullous pemphigoid: physiopathology, clinical features and management. *Adv Dermatol.* 2007;23:257-88.

24. Di Zenzo G, Thoma-Uszynski S, Fontao L, Calabresi V, Hofmann SC, Hellmark T, et al. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. *Clin Immunol Orlando Fla.* sept 2008;128(3):415-26.

25. Di Zenzo G, Thoma-Uszynski S, Calabresi V, Fontao L, Hofmann SC, Lacour J-P, et al. Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study. *J Invest Dermatol.* nov 2011;131(11):2271-80.

26. Heymann WR. Bullae for You: The Increasing Importance and Implications of Drug-induced Bullous Pemphigoid. *J Am Acad Dermatol.* 1 oct 2018;

27. Chijiwa C, Takeoka S, Kamata M, Tateishi M, Fukaya S, Hayashi K, et al. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid. *J Dermatol.* mai 2018;45(5):596-9.

28. Kawaguchi Y, Shimauchi R, Nishibori N, Kawashima K, Oshitani S, Fujiya A, et al. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients. *J Diabetes Investig.* 19 juin 2018;

# **TIME-RELATED EVOLVING CLINICAL PATTERN OF BULLOUS PEMPHIGOID: A MONOCENTER RETROSPECTIVE SURVEY OF 312 CASES**

Elise Dandache<sup>1</sup>, Aurélie Du Thanh<sup>1</sup>, Bernard Guillot<sup>1</sup>, Céline Girard<sup>1</sup>,  
Didier Bessis<sup>1</sup>, Olivier Dereure<sup>1</sup>

1: Department of Dermatology, University of Montpellier and INSERM  
U1058, Montpellier, France

Correspondence to:

Olivier Dereure  
Department of Dermatology  
Hôpital Saint-Eloi  
University of Montpellier and INSERM U1058  
80 avenue Augustin Fliche  
Montpellier Cedex 5 France  
Tel : (33) 467 33 69 06  
Fax : (33) 467 33 69 58  
Email: [o-dereure@chu-montpellier.fr](mailto:o-dereure@chu-montpellier.fr)

Key words: bullous pemphigoid, atypical presentation, clinical patterns

Word count: 5923

References: 28

Figures: 0

Table: 5

Conflict of interest: none to declare

## ABSTRACT

**Background** : The clinical spectrum of Bullous Pemphigoid (BP) may have changed over time as suggested by the recently growing occurrence of unusual clinical features reported in daily practice. Accordingly a retrospective, large-scale time-related analysis was conducted to reappraise BP clinical profile during the last 2 decades and to reassess the validity of a set of 4 previously established clinical criteria.

**Patients and methods** : All well-documented BP patients diagnosed between January 2001 and April 2017 in a tertiary referral center were included and the following data were collected : baseline characteristics of patients, extent of the disease, distribution and type of cutaneous lesions, presence of mucous lesions, presence of at least one atypical clinical (topographical or lesional) feature, presence or absence of at least 3 of previously validated diagnostic clinical criteria. In order to identify a possible time-related shift of clinical features, data from 4 chronological groups of 4 years were statistically compared.

**Results** : 312 patients were finally included and analyzed. At least 3 of the 4 classical criteria were present in 278 patients (89.1%), but with a trend toward a steady decrease of relevance over time (G1 93.0% vs G4 83.8%,  $p$  0.067). The most frequent missing criteria were absence of mucosal involvement followed by absence of head and neck involvement. 206 patients (66.0%) displayed at least one atypical clinical feature and chronological analysis confirmed a significant time-related increase of atypical pattern frequency (G1 57.9%, G4 73.7%,  $p$  0.041). Head and neck, palmoplantar, mucosae involvement were observed in 56 (17.9%), 151 (48.4%) and 58 (18.6%) patients respectively, with an upward, although non significant trend between G1 and G4 ( $p$  0.071,  $p$  0.088,  $p$  0.094 for these 3 items respectively).

**Discussion** : Clinical presentation of BP seems to have evolved over time with a progressively higher proportion of atypical topographical and/or lesional characteristics, mainly regarding mucous membrane, head and neck and palmo-plantar involvement. This shift probably underlies the progressive reduction of the percentage of BP patients fulfilling at least 3 of the 4 BP previously validated diagnostic criteria even though these criteria remain robust in our study. Environmental causes, mainly drugs might affect clinical presentation of BP since a higher frequency of mucosal lesions has been recently reported in dipeptidyl peptidase 4 inhibitors (DPP4is)-induced BP compared to other BP patients.

**Conclusion** : BP clinical spectrum seems to have changed with the emergence of more atypical forms, perhaps under the influence of etiological factors including drugs.

## **ABBREVIATIONS AND ACRONYMS LIST**

BP: bullous pemphigoid

BPag1: Bullous Pemphigoid antigen 1

Bpag2: Bullous Pemphigoid antigen 2

DIBP : Drug-induced bullous pemphigoid

DIF: direct immunofluorescence

DPP4is: dipeptidyl peptidase 4 inhibitors

ELISA: Enzyme-Linked Immunosorbent Assay

G1-G4: group 1-group 4

IgG: immunoglobulin G

PD-1/PD-L1 inhibitors: programmed cell death 1/ programmed death ligand 1

PMSI: programme de médicalisation des systèmes d'information

## INTRODUCTION

Bullous pemphigoid (BP) is the most frequent autoimmune bullous disease and mainly affects the elderly population. (2,3). Causative autoantibodies target structural proteins of hemidesmosomes, mainly 230 kD BPag1 and 180 kD BPag2 at the dermo-epidermal junction, resulting in subepidermal blistering within the upper part of lamina lucida. The annual world incidence has been estimated between 4.5 and 14 new cases per million per year (4–9) and may be higher in France with 21.7 new cases per million per year. This latter value is about 3 times higher than the estimated incidence 15 years ago, according to a recent survey (10). The overall 1-year survival rate is 62% (10) with a death hazard three to six times higher than in the age- and gender-matched general population, mainly related to general health status, comorbidities with a significant association with degenerative and vascular neurological disorders and to treatment complications especially of systemic steroids rather than to the severity of the blistering disease itself (10).

Clinically, BP is mainly characterized by pruritus, often isolated at onset of the disease, associated with inflammatory, urticaria-like lesions and a widespread or more localized bullous eruption characteristically developing on inflammatory skin and predominant on some body areas. (15). Contrasting with other subepithelial auto-immune blistering diseases, scarring is theoretically absent and the disease usually spares head and neck regions and mucous membranes (1,16)(17). BP diagnosis is based on a combination of consistent clinical features, subepidermal cleavage with an eosinophil-rich infiltrate on histopathological examination and IgG and/or C3 deposits at the dermoepidermal junction on direct immunofluorescence (IF) microscopy. Circulating anti-BPAG1 and mainly anti-BPAG2 autoantibodies are usually detected on immunoblot or by ELISA (1,18).

In 1998, The French Auto-immune Bullous Diseases taskforce proposed and validated a set of 4 clinical criteria highly consistent with BP diagnosis that consisted of age greater than 70 years, absence of atrophic scars, absence of mucosal involvement and absence of predominant bullous lesions on the neck and head. If 3 of these 4 characteristics were present, a clinical diagnosis of BP could be made with a sensitivity of 90%, a specificity of 83% and a positive predictive value of 95% (19). In 2004 the same taskforce reappraised the validity of these clinical criteria for BP diagnosis using immunoblot analysis of patients' sera as the main diagnostic criterion (18) which confirmed a sensitivity of 86%, a specificity of 90% and an excellent predictive diagnostic value of more than 95% if at least 3 of these 4 clinical criteria were present, therefore confirming the interest of this set of clinical features for the rapid



diagnosis of BP (18).

However, clinical spectrum of diseases may change over time and recently a number of unusual clinical features appear to have emerged in some BP patients including merely or predominant palmo-plantar blistering, extensive erosions and a higher than expected occurrence of intrabuccal and head and neck lesions. Accordingly a monocenter retrospective study based on a large cohort of well-documented BP was designed to document this possible shift of BP clinical pattern over time with two main complementary objectives: (i) to describe the possible occurrence of unusual/atypical clinical patterns of BP with respect to lesions' topography and/or clinical subtype and their possible time-related emergence over the last two decades (ii) to reassess the validity of the four aforementioned clinical diagnostic criteria over time in this setting of possibly increasing frequency of atypical features.

## **PATIENTS AND METHODS**

### Patients' selection procedure

All patients with a well-established diagnosis of BP and treated in the department of dermatology of the University of Montpellier, a tertiary reference center, from January 2001 to April 2017 were considered for inclusion. The identification of patients was based on a list of individuals obtained from the computerized epidemiological database in use in French healthcare establishments through a specific coding (PMSI) with bullous pemphigoid selected as principal, related or associated diagnosis. Data from selected patients were then retrospectively collected using electronic medical records from the local medical software and anonymized before analysis.

In a second step, BP diagnosis was verified in all patients selected through this procedure using consistent histological (subepidermal blister with eosinophil-rich dermal infiltrate) and direct immunofluorescence (IgG and/or C3 linear deposits at the dermoepidermal junction) data obtained on initial skin biopsies. BP180 ELISA was often performed on patients' sera, particularly in case of unclear diagnosis mainly owing to inconclusive and/or discrepant histological and DIF data. Patients with diagnostic or coding errors (most often other auto-immune bullous diseases or skin infections) or patients for whom clinical details were missing were excluded of final analysis.

### Collected data

The following data were systematically collected from selected patients' files:

- Baseline characteristics of patients: age at diagnosis, gender, presence and type of associated neurological disorder.
- Initial extent of the disease: multibullous (at least 10 new blisters daily), paucibullous (less than 10 blisters daily) or nonbullous subset (solitary pruritus or associated with prurigo-like lesions or excoriations or merely inflammatory lesions); localized disease (one affected body area only).
- Initial distribution of cutaneous lesions: limbs, trunk, head and neck, palmo-plantar regions
- Type of non-bullous cutaneous lesions: urticaria-like or eczematous

plaques, atrophic scars, erythematous lesions, extensive skin erosions.

- Presence, clinical pattern and topography of mucous membranes lesions.
- Histological, DIF and if applicable ELISA findings
- Presence or absence of at least 3 of the clinical criteria of BP validated in prior reports by the French taskforce (19).

#### Chronological group and time-related comparative analysis of data

In order to identify a possible time-related shift of clinical features, patients were chronologically divided in four groups of 4 years each:

- Group 1 (G1) diagnosed between January 2001 and December 2004
- Group 2 (G2) diagnosed between January 2005 and December 2008
- Group 3 (G3) diagnosed between January 2009 and December 2012
- Group 4 (G4) diagnosed between January 2013 and April 2017

The following data were described as figures and percentages, and Pearson's Chi-squared test or Fisher's exact test according to samples' size were used to compare these data between the 4 chronological groups (G1, G2, G3, G4) and more specifically between G1 and G4 to search for a possible time-related shift of clinical pattern:

- presence of at least one atypical clinical element, either topographic or lesional, formally defined as involvement of palmoplantar regions, head and neck or mucous membranes (topographic atypical features) and extensive erosions, erythematous or eczematous lesions, atrophic scars (lesional atypical features)

- presence/absence of at least 3 of 4 of the above-mentioned validated clinical BP diagnostic criteria

## RESULTS

### Baseline characteristics of patients

360 files were initially selected through PMSI database survey but only 312 patients (86.67%) were retained for final analysis. 48 patients were excluded: 17 for diagnostic errors (3 prurigo or isolated pruritus, 1 eczema, 3 mucous membrane pemphigoid, 1 cutaneous adverse drug reaction, 1 bullous impetigo, 2 epidermolysis bullosa acquisita, 2 pemphigoid gestationis, 1 linear IgA disease, 2 pemphigus, 1 eosinophilic cellulitis) and 31 for missing clinical details. 146 (46.8%) were female and 166 (53.3%) male patients. Age ranged from 49 to 106 years (median 82.0 years, Q1 74.8 – Q3 88.0 years). 165/313 (52.9%) patients had a medical history of neurological disease (degenerative, vascular or neuropsychiatric) (Table A). Histological and DIF findings were consistent with BP in 285 (91.3%) and 263 (84.3%) patients respectively but all patients had at least one consistent criteria. BP180 ELISA was performed in 224 patients and was positive for 197 (87.9%) patients (Table B).

### Overall descriptive analysis of initial clinical pattern (Table C).

#### *Topographic distribution of lesions*

Initially non bullous, paucibullous, multibullous, or localized BP was diagnosed in 12 (3.8%), 137 (43.9%), 158 (50.6%) and 5 (1.6%) patients respectively.

A typical topographic distribution of lesions (limbs and abdomen) was solely or mainly observed in a minority of patients (121; 38.8%) while head and neck, palmo-plantar regions and at least one mucosae were affected in 56 (17.9%), 151 (48.4%) and 58 (18.6%) patients respectively regardless of the relative importance of these latter lesions regarding overall location of skin and mucosae changes. Conversely, a predominant atypical distribution including head and neck, palmo-plantar and/or mucosal involvement was observed in 191 (61.2%) cases including 146 (46.8%) cases with exclusive atypical topography. As regards mucosal involvement, oral mucosae was mainly affected in 52 (16.67%) cases followed by genital mucosae in 14 (4.49%) cases including 6 cases with exclusive genital involvement; no ocular involvement was reported.

### *Clinical pattern of lesions*

A typical clinical pattern of urticaria-like plaques and blisters was exclusively present in 234 (75%) cases. 50 (16.0%) patients presented with blisters with no urticaria-like plaques nor atypical clinical features. Conversely, at least one atypical/unusual clinical feature was observed in 28 (9.0%) patients overall including 9 (2.9%) patients where atypical features were solely present: atrophic scars in 3 (0.96%), eczematous lesions in 14 (4%), erythematous lesions in 5 (2%) and extensive erosions in 7 (2%) patients respectively.

Overall, 206/312 (66.0%) patients displayed at least one atypical element, either lesional or topographic with a ratio atypical topography / atypical clinical features of 6.8 (191/28). 13 (4.2%) patients displayed a totally atypical form (both lesional and topographic) while 95 (30.4%) showed no atypical element whatsoever.

### *Presence/absence of formerly validated clinical criteria for BP diagnosis*

(Table D)

Overall, the 4 criteria were present at diagnostic in 196 (62.82%) patients while 3, 2, 1 or 0 criteria were present in 82 (26.28%), 30 (9.61%), and 4 (1.28%) patients respectively. Accordingly, at least 3 of 4 criteria were present in 278 (89.10%) patients. By order of frequency, the missing criteria were the absence of mucosal involvement (58 patients, 18.59%), of predominant bullous lesions on the neck and head (56 patients, 17.95%), an age greater than 70 years (41 patients, 13.14%) and the absence of atrophic scars (3 patients, 0.96%).

### Comparative data analysis in chronological groups (Table C and D)

Proportion of woman and median age were similar across the 4 groups (G1 63%, G2 48%, G3 51%, G4 53%,  $p = 0.165$ ; G1 83.0 years, G2 81.5 years, G3 83.0 years, G4 81.0 years,  $p = 0.153$  respectively) and between G1 and G4 ( $P = 0.242$  and  $0.294$  respectively). The association with neurological comorbidities, irrespective of their subtype, increased over time, but with no significant difference between the 4 groups (G1 43.8%, G2 47.6%, G3 54.0%, G4 61.6%,  $p = 0.063$ ) nor between G1 and G4 ( $p = 0.045$ ). The proportion of multibullous BP was similar in the 4 groups (G1 47.4%, G2 45.1%, G3

52.7%, G4 55.6%,  $p= 0.508$ ) and between G1 and G4 ( $p= 0.324$ ).

The percentage of patients displaying at least one atypical, either lesional or topographic clinical feature steadily increased over time in the 4 chronological groups: G1 57.9%, G2 59.8%, G3 68.9%, G4 73.7%, with no overall difference ( $p = 0.111$ ) between the 4 groups but a significant difference ( $p = 0.041$ ) was observed between G1 and G4. No difference was identified between the 4 groups regarding the proportion of exclusively atypical disease regarding both topographic and lesional pattern (G1 5.3%, G2 <0.1%, G3 <0.1%, G4 5.0%) ( $p 0.859$ ) nor between G1 and G4 ( $p = 1.000$ ). Regarding the proportion of exclusively typical diseases as to both topographic and lesional features, a steady but non significant decrease was identified over time when comparing the four chronological groups (G1 40.3%, G2 34.1%, G3 24.3%, G4 26.3%,  $p = 0.151$ ) but a more marked trend (although still non significant) was observed when comparing G1 and G4 ( $p = 0.068$ ).

The presence of a mere or predominant typical topographic pattern (mainly involving limbs and abdomen) was statistically different in the 4 groups (G1 to G4: 43.8%, 37.8%, 23.0%, 48.5% respectively;  $p= 0.006$ ) but with no clear chronological shift toward progressive decrease over time as no significant difference between G1 and G4 ( $p= 0.577$ ) was found. As to the initial presence of typical urticaria-like plaques, no significant difference was identified between the 4 groups (75.4%, 69.5%, 73.0%, 80.8% respectively;  $p= 0.372$ ) nor between G1 and G4 ( $p 0.126$ ).

Comparative analysis of data regarding patients with predominant atypical distribution of lesions revealed a trend to steady increase over time between the 4 groups (G1 50.9%, G2 54.9%, G3 66.2%, G4 68.7%) ( $p= 0.070$ ) and a statistically significant difference between G1 and G4 ( $p= 0.027$ ). Conversely, the specific analysis of patients with exclusive atypical topography failed to identify significant difference between the 4 groups (G1 42.1%, G2 42.7%, G3 58.1%, G4 44.4%) ( $p= 0.166$ ) nor between G1 and G4 ( $p= 0.777$ ).

The percentage of patients with at least one atypical lesional subtype was not different between the 4 groups (G1 10.5%, G2 0.1%, G3 5.4%, G4 11.1%) ( $p= 0.595$ ) nor between G1 and G4 ( $p= 0.910$ ). The restricted number of patients with exclusively

atypical lesions (9) precluded any significant statistical analysis between chronological groups.

The main atypical features identified from files' review among predefined atypical elements (involvement of palmoplantar regions, of head and neck or of mucous membranes, extensive erosions, erythematous or eczematous lesions, atrophic scars) were individually submitted to a specific time-related analysis and in most cases no significant difference was identified between the 4 chronological groups nor between G1 and G4 more particularly. However, a trend toward a significant difference was observed between G1 and G4 for oral lesions (10.5% vs 22.2%;  $p=0.075$ ) and for head and neck lesions (12.3% vs 24.2%;  $p=0.071$ ) with a steady increase in frequency over time for both features, highly consistent with overall clinical feeling. Additionally, a significant difference between the 4 groups ( $p=0.026$ ) and a trend to significant difference between G1 and G4 ( $p=0.060$ ) were observed for extensive erosive lesions but the limited size of the sample must be pointed out (G1 7.0%, G2 0%, G3 1.4%, G4 1.0%).

Finally, the percentage of patients fulfilling at least 3 of 4 clinical criteria of BP diagnosis was no statistically significant difference between the 4 groups (93% G1, 91.5% G2, 90.5% G3, 83.8% G4;  $p=0.227$ ) despite a steady decrease over time but a trend toward significance was observed between G1 and G4 ( $p=0.067$ ). Conversely, a significant decrease of the percentage of patients fulfilling the 4 clinical criteria was observed over time (75.4% G1, 68.3% G2, 62.2% G3, 51.5% G4 :  $p=0.016$ ) and between G1 and G4 ( $p=0.003$ ).

## DISCUSSION

This retrospective analysis based on a large cohort of 312 cases of BP initially diagnosed over a long period of time (approximately 2 decades) is the first study ever specifically designed to evaluate a possible shift over time of BP clinical profile and of the relevance of the previously established set of 4 clinical criteria for BP diagnosis, with a specific emphasis on the frequency and spectrum of atypical clinical features related to either topographic or lesional features.

This large-scale descriptive, monocenter series mainly shows a significant increase over time of the proportion of patients displaying at least 1 atypical feature, either topographic or lesional or both, with head and neck, palmoplantar and mucous membranes involvement being by far the more frequently observed atypical features compared to atypical clinical subsets of lesions. In parallel, the proportion of patients with an exclusively typical pattern regarding both clinical subtype and topography of lesions tended to decrease over time even though only a trend was observed. Likewise, the proportion of patients fulfilling at least 3 of the 4 previously validated diagnostic criteria steadily decreased over the past two decades but with no significant difference, meaning that these criteria are probably still robust. Conversely, the proportion of patients fulfilling the 4 criteria significantly decreased during the period of the study.

BP severity regarding disease extension was similar across the 4 chronological groups and the rare localized form cases were all pretibial. Baseline characteristics of patients reflected previous data regarding age, sex ratio and association to neurological disorders (1,12,13,20-22).

Only few past studies aimed to record atypical clinical features in BP, although based on a lower number of patients compared to our series and none of them were specifically designed to appraise a possible shift of clinical profile over time. Della Torre carried out a prospective nationwide cohort in Switzerland between 1 January 2001 and 31 December 2002 including 117 patients: 17.1% patients had only excoriations, eczematous and/or urticarial infiltrated lesions, head/neck as well as palmo-plantar involvement were found in up to 20% of patients, while mucosal lesions were present in 14.5% of the cases (16). Esmaili carried out a descriptive study in 2012 in Iran on 122



patients with documented bullous pemphigoid and found oral lesions in 27% cases, non-specific rash in 19.7%, eczema in 7.4%, genital lesions in 4.1%, face in 25.4%, scalp in 17.2%, palm and sole in 8.2% (20). Chang reported in 1996 in 86 cases of Taiwan 3 cases of dishydrosiform BP and mucous involvement in 12.8% cases (21). Di Zenzo reported 10 to 20% involvement of oral mucosae in a prospective study of 49 cases in 2008 (3). Eventually, Kridin included 82 patients with BP and diabetes in 2018 and revealed that mucosal involvement was present in 22.2% patients taking dipeptidyl peptidase 4 inhibitor (DPP4is) vs 6.5% in other patients (22).

Proportion of head and neck involvement was the same in our series as previous study. A bigger proportion of mucosal and palmoplantar involvement was observed in our series compared to previous study. However, the proportion of patients displaying an atypical pattern was smaller than in some previous other studies but such features are poorly described in literature. Literature data regarding the presence of clinical atypical features and our main results are summarized and compared in Table E.

In 1998, the the French Taskforce for Bullous disorders established a set of 4 clinical BP diagnosis criteria (age greater than 70 years, absence of atrophic scars, absence of mucosal involvement and absence of predominant bullous lesions on the neck and head) ; if 3 of these 4 characteristics were present, a diagnosis of BP could be made with a sensitivity of 90%, a specificity of 83% and a positive predictive value of 95% (19). Some years later, the validity of these clinical criteria were reassessed using immunoblot analysis of patient sera as the main diagnostic element, confirming a high degree of sensitivity (86%) and of specificity (90%) and an excellent prognostic positive value over 95% among patients with various subepidermal auto-immune bullous disorders if 3 of these 4 clinical criteria were fulfilled (18). If these results confirmed the interest of this set of clinical criteria for BP rapid diagnosis, no further study reappraised the validity of these criteria nor specifically investigated a possible shift of their relevance over time. In our study the overall percentage of patients fulfilling at least 3 criteria was still high (89.1%) favouring a persistent robustness of this set of criteria but a trend toward a steady decrease of this percentage over time must be pointed out especially when taking in account the two extreme chronological groups (93.0% vs 83.8% respectively;  $p = 0.067$ ). The most frequent missing criteria were the absence of

mucosal involvement (missing in 18.6% of patients) and of predominant bullous lesions on the head and neck (missing in 17.9% of patients), results that match quite well the data regarding the steady increase over time of the frequency of these atypical features.

A number of hypothesis underlying this possible shift to a higher percentage of atypical features in BP over time may be raised. First, it cannot be ruled out that higher attention was recently paid to atypical features in PB with a more frequent recording of such unusual elements in clinical files as a consequence; in this setting, the observed time-related increase of atypical features might be at least partially artifactual. A second hypothesis could be related to etiological factors and more particularly to recently-introduced drugs that can act as antigenic haptens binding to and/or modifying basement membrane proteins (23–25). More specifically, dipeptidyl peptidase 4 inhibitors (DPP4is) currently largely used in diabetic patients has been recently repeatedly involved in BP occurrence and associated with a threefold increased risk for BP. Patients with DPP4is-induced BP display a higher mucosal involvement compared to non DPP4is-related BP (22,26–28). However, our study was not designed to evaluate the impact of medication on clinical presentation of BP. Further study are needed to more adequately investigate a possible relationship between medication uptake and the occurrence of atypical forms of BP.

## **CONCLUSION**

A shift in the clinical spectrum of BP seems to have occurred during the past two decades with the emergence of more atypical forms mainly regarding the distribution of lesions. These changes in clinical pattern might at least partially be related to environmental causes, such as newly introduced drugs but further, large-scale prospective investigations are warranted to support this hypothesis.

**Table A. Baseline characteristics of patients**

	G1	G2	G3	G4	Total	P-value	
						4 groups	G1 vs G4
Number of patients	57 (18.3%)	82 (26.3%)	74 (23.7%)	99 (31.7%)	312 (100%)		
Sex : Female/Male	F 36 (63.2%) / M 21 (36.8%)	F 39 (47.6%) / M 43 (52.4%)	F 38 (51.3%) / M 36 (48.6%)	F 53 (53.5%) / M 46 (46.4%)	F 146 (46.8) / M 166 (53.3%)	0.165	0.242
Median age at diagnosis (Q1-Q3)	83.0 years (Q1 76.0- Q3 88.0)	81.5 years (Q1 75.0- Q3 87.0)	83.0 years (Q1 77.3- Q3 88.0)	81.0 years (Q1 73.0- Q3 89.0)	82.0 years (Q1 74.8- Q3 88.0)	0.153	0.294
Neurological disorders	25 (43.9%)	39 (47.6%)	40 (54.0%)	61 (61.6%)	165 (52.9%)	0.063	0.045

SD, standard deviation ; G1 to G4, chronological groups ; Q1, first quartile ; Q3, third quartile

**Table B. Histological, direct immunofluorescence and ELISA findings**

	G1	G2	G3	G4	Total
Compatible histology	54/57 (94.7%)	73/82 (89.0%)	68/74 (91.9%)	90/99 (90.9%)	285/312 (91,3%)
DIF : linear IgG and/or C3 deposits at the DEJ	45/57 (78.9%)	72/82 (87.8%)	60/74 (81.1%)	86/99 (86.9%)	263/312 (84,3%)
ELISA if performed : detection of anti-BPAG2 antibodies	3/5 (60.0%)	51/54 (94.4%)	61/69 (88.4%)	82/96 (85.4%)	197/224 (87,9%)

DEJ, dermoepidermal junction; DIF, direct immunofluorescence; ELISA, Enzyme-Linked ImmunoSorbent Assay; G1 to G4, chronological groups

**Table C. Clinical patterns of bullous pemphigoid**

	G1	G2	G3	G4	Total	P-value	
						Comparison 4 groups	Comparison G1 vs G4
<b>Topography</b>							
- Typical	25 (43.9%)	31 (37.8%)	17 (23.0%)	48 (48.5%)	121 (38.8%)	0.006	0.580
* Including exclusive typical topography	20 (35.1%)	21 (25.6%)	11 (14.9%)	24 (24.2%)	76 (24.4%)	0.064	0.147
Trunk and flexural involvement	25 (43.9%)	31 (37.8%)	17 (23.0%)	48 (48.5%)	121 (38.8%)	0.006	0.577
- Atypical	29 (50.9%)	45 (54.9%)	49 (66.2%)	68 (68.7%)	191 (61.2%)	0.070	0.027
* Including exclusive atypical topography	24 (42.1%)	35 (42.7%)	43 (58.1%)	44 (44.4%)	146 (46.8%)	0.166	0.777
Head and neck involvement	7 (12.3%)	11 (13.4%)	14 (18.9%)	24 (24.2%)	56 (17.9%)	0.165	0.071
Palmo-plantar involvement	23 (40.3%)	35 (42.7%)	39 (52.7%)	54 (54.5%)	151 (48.4%)	0.248	0.088
Involvement of ≥ 1 mucosae	7 (12.3%)	15 (18.3%)	13 (17.6%)	23 (23.2%)	58 (18.6%)	0.435	0.094
* oral mucosae	6 (10.5%)	12 (14.6%)	12 (16.2%)	22 (22.2%)	52 (16.7%)	0.293	0.075
* genital mucosae	0 (0.0%)	6 (7.3%)	3 (4.0%)	5 (5.0%)	14 (4.5%)	0.202	0.159
* ocular mucosae	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1.000	1.000
<b>Clinical features</b>							
- Typical	51 (89.4%)	75 (91.4%)	70 (94.6%)	88 (88.9%)	284 (91.0%)	0.595	0.910
* Including exclusive typical clinical features	41 (71.9%)	50 (61.0%)	51 (68.9%)	73 (73.7%)	215 (68.9%)	0.292	0.806
Urticaria-like plaques	43 (75.4%)	57 (69.5%)	54 (73.0%)	80 (80.8%)	234 (75.0%)	0.372	0.429
Blisters solely	8 (14.0%)	18 (21.9%)	16 (21.6%)	8 (8.1%)	50 (16.0%)	0.034	0.238
- Atypical	6 (10.5%)	7 (0.1%)	4 (5.4%)	11 (11.1%)	28 (9.0%)	0.595	0.910
* Including exclusive atypical clinical features	4 (7.0%)	0 (0%)	1 (0.01%)	4 (4.0%)	9 (2.9%)	0.057	0.465
Presence of atrophic scars	0 (0.0%)	1 (1.2%)	1 (1.4%)	1 (1.0%)	3 (1.0%)	1.000	1.000
Eczematous lesions	3 (5.3%)	5 (6.1%)	1 (1.4%)	5 (5.0%)	14 (4.5%)	0.481	1.000
Erythemasquamous lesions	3 (5.3%)	0 (0.0%)	1 (1.4%)	1 (1.0%)	5 (5.0%)	0.078	0.139
Extensive erosive lesions	4 (7.0%)	0 (0.0%)	1 (1.4%)	1 (1.0%)	7 (2.2%)	0.026	0.060
<b>All atypical patterns (topography or clinical features)</b>	<b>33 (57.9%)</b>	<b>49 (59.8%)</b>	<b>51 (68.9%)</b>	<b>73 (73.7%)</b>	<b>206 (66.0%)</b>	<b>0.111</b>	<b>0.041</b>
* Ratio atypical topography/atypical features	4.8 (29/6)	6.4 (45/7)	12.2 (49/4)	6.2 (68/11)	6.8 (191/28)	0.570	0.656
* Including exclusive atypical patterns	3 (5.3%)	3 (< 0.1%)	2 (< 0.1%)	5 (5.0%)	13 (4.2%)	0.859	1.000
<b>All typical patterns (topography or clinical features)</b>	<b>49 (86.0%)</b>	<b>65 (79.3%)</b>	<b>58 (78.4%)</b>	<b>86 (86.9%)</b>	<b>258 (82.7%)</b>	<b>0.682</b>	<b>0.267</b>
* Including exclusive typical patterns	23 (40.3%)	28 (34.1%)	18 (24.3%)	26 (26.3%)	95 (30.4%)	0.151	0.068
<b>Extent of the disease</b>							
Localized	2 (3.5%)	3 (3.7%)	0 (0.0%)	0 (0.0%)	5 (1.6%)		
Paucibullous	24 (42.1%)	41 (50.0%)	32 (43.2%)	40 (40.4%)	137 (43.9%)		
Multibullous	27 (47.4%)	37 (45.1%)	39 (52.7%)	55 (55.6%)	158 (50.6%)	0.251	0.205
Nonbullous	4 (7.0%)	1 (1.2%)	3 (4.1%)	4 (4.0%)	12 (3.8%)		

G1 to G4, chronological group61.2

**Table D. Presence of clinical criteria of Vaillant and al. (absence of atrophic scars, absence of head and neck involvement, absence of mucosal involvement, and age greater than 70 years)**

	<b>G 1</b>	<b>G 2</b>	<b>G 3</b>	<b>G 4</b>	<b>Total</b>
<b>≤ 1 criteria</b>	1 (1.75%)	1 (1.22%)	1 (1.35%)	1 (1.01%)	4 (1.28%)
<b>2 criteria</b>	3 (5.26%)	6 (7.32%)	6 (8.11%)	15 (15.15%)	30 (9.62%)
<b>3 criteria</b>	10 (17.54%)	19 (23.17%)	21 (28.38%)	32 (32.32%)	82 (26.28%)
<b>4 criteria</b>	43 (75.44%)	56 (68.29%)	46 (62.16%)	51 (51.52%)	196 (62.82%)
<b>≥ 3/4 criteria</b>	53 (93.0%)	75 (91.5%)	67 (90.5%)	83 (83.8%)	278 (89.1%)

**P-value ≥ 3/4 criteria :** comparison /4 groups : p 0.227 ; comparison/G1 vs G4 : p 0.067

**P-value 4/4 criteria :** comparison/4 groups : p 0.016 ; comparison/G1 vs G4 : p 0.003

**Table E. Atypical clinical features in BP patients as reported in the literature**

<b>Study</b>	<b>Number of patients</b>	<b>Atypical topography</b>	<b>Atypical lesional features</b>
<b>Chang 1996 (28)</b>	86	12.8% mucosae	3.5% eczematous lesions
<b>Di Zenzo 2008 (3)</b>	49	10 to 20% oral mucosae	
<b>Della Torre 2012 (16)</b>	117	20% head and neck 14.5% mucosae	17.1% exclusive atypical lesions (excoriations, eczematous lesions)
<b>Esmaili 2012 (28)</b>	122	17.2% scalp 25.4% face 8.2% palm and sole 27% oral mucosae 4.1% genital mucosae	7.4% eczematous lesions 19.7% non specific rash
<b>Kridin 2018 (22)</b>	82	22.2% mucosae with DPP4is, 6.5% mucosae without DPP4is	
<b>This study, 2018</b>	312	<b>61.2% atypical topography</b> 17.9% head and neck 48.4% palm and sole 18.6% mucosae	<b>9.0% atypical lesions</b> 1.0% atrophic scars 4.5% eczematous lesions 5.0% erythematous lesions 2.2% extensive erosive lesions 3.7% non bullous form

---

DPP4is, dipeptidyl peptidase 4 inhibitors



## Reference

1. Schmidt E, della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. *Immunol Allergy Clin North Am.* mai 2012;32(2):217-32, v.
2. Zillikens D, Mascaro JM, Rose PA, Liu Z, Ewing SM, Caux F, et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. *J Invest Dermatol.* nov 1997;109(5):679-83.
3. Di Zenzo G, Thoma-Uszynski S, Fontao L, Calabresi V, Hofmann SC, Hellmark T, et al. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. *Clin Immunol Orlando Fla.* sept 2008;128(3):415-26.
4. Bernard P, Vaillant L, Labeille B, Bedane C, Arbeille B, Denoeux JP, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. *Arch Dermatol.* janv 1995;131(1):48-52.
5. Increased risk of bullous pemphigoid in male and very old patients: A population-based study on incidence. - PubMed - NCBI [Internet]. [cité 24 juill 2018]. Disponible sur: <https://www.ncbi.nlm.nih.gov/pubmed/10426901>
6. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJP, West J. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. *BMJ.* 9 juill 2008;337:a180.
7. Gudi VS, White MI, Cruickshank N, Herriot R, Edwards SL, Nimmo F, et al. Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland. *Br J Dermatol.* août 2005;153(2):424-7.
8. Cozzani E, Parodi A, Rebora A, Delmonte S, Barile M, Nigro A, et al. Bullous pemphigoid in Liguria: a 2-year survey. *J Eur Acad Dermatol Venereol JEADV.* juill 2001;15(4):317-9.
9. Serwin AB, Bokinić E, Piascik M, Masny D, Chodynicka B. Epidemiological and clinical analysis of pemphigoid patients in northeastern Poland in 2000-2005. *Med Sci Monit Int Med J Exp Clin Res.* août 2007;13(8):CR360-364.
10. Joly P, Baricault S, Sparsa A, Bernard P, Bédane C, Duvert-Lehembre S, et al. Incidence and mortality of bullous pemphigoid in France. *J Invest Dermatol.* août 2012;132(8):1998-2004.
11. Lai YC, Yew YW, Lambert WC. Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol JEADV.* déc 2016;30(12):2007-15.
12. Cordel N, Chosidow O, Hellot M-F, Delaporte E, Lok C, Vaillant L, et al. Neurological disorders in patients with bullous pemphigoid. *Dermatol Basel Switz.* 2007;215(3):187-91.
13. Gambichler T, Segert H, Höxtermann S, Schmitz L, Altmeyer P, Teegen B. Neurological disorders in patients with bullous pemphigoid: clinical and experimental investigations. *J Eur Acad Dermatol Venereol JEADV.* sept 2015;29(9):1758-62.
14. Milani-Nejad N, Zhang M, Kaffenberger J. The association between bullous pemphigoid and neurological disorders: a systematic review. *Eur J Dermatol EJD.* 1 oct 2017;27(5):472-81.
15. de Quatrebarbes J, Joly P. [Bullous pemphigoid]. *Rev Prat.* 15 juin 2005;55(11):1165-8.
16. della Torre R, Combescure C, Cortés B, Marazza G, Beltraminelli H, Naldi L, et al. Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort. *Br J Dermatol.* nov 2012;167(5):1111-7.
17. Bakker CV, Terra JB, Pas HH, Jonkman MF. Bullous Pemphigoid as Pruritus in the Elderly: A Common Presentation. *JAMA Dermatol.* 1 août 2013;149(8):950-3.
18. Joly P, Courville P, Lok C, Bernard P, Saiag P, Dreno B, et al. Clinical criteria for the diagnosis of bullous pemphigoid: a reevaluation according to immunoblot analysis of patient sera. *Dermatol Basel Switz.* 2004;208(1):16-20.
19. Vaillant L, Bernard P, Joly P, Prost C, Labeille B, Bedane C, et al. Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French Bullous Study Group. *Arch Dermatol.* sept

1998;134(9):1075-80.

20. Esmaili N, Hallaji Z, Soori T, Chams Davatchi C. Bullous pemphigoid in Iranian patients: a descriptive study on 122 cases. *Acta Med Iran.* 2012;50(5):335-8.
21. Chang YT, Liu HN, Wong CK. Bullous pemphigoid--a report of 86 cases from Taiwan. *Clin Exp Dermatol.* janv 1996;21(1):20-2.
22. Kridin K, Bergman R. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients. *JAMA Dermatol* [Internet]. 8 août 2018 [cité 14 août 2018]; Disponible sur: <https://jamanetwork.com/journals/jamadermatology/fullarticle/2695085>
23. Di Zenzo G, Marazza G, Borradori L. Bullous pemphigoid: physiopathology, clinical features and management. *Adv Dermatol.* 2007;23:257-88.
24. Di Zenzo G, Thoma-Uszynski S, Fontao L, Calabresi V, Hofmann SC, Hellmark T, et al. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. *Clin Immunol Orlando Fla.* sept 2008;128(3):415-26.
25. Di Zenzo G, Thoma-Uszynski S, Calabresi V, Fontao L, Hofmann SC, Lacour J-P, et al. Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study. *J Invest Dermatol.* nov 2011;131(11):2271-80.
26. Heymann WR. Bullae for You: The Increasing Importance and Implications of Drug-induced Bullous Pemphigoid. *J Am Acad Dermatol.* 1 oct 2018;
27. Chijiwa C, Takeoka S, Kamata M, Tateishi M, Fukaya S, Hayashi K, et al. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid. *J Dermatol.* mai 2018;45(5):596-9.
28. Kawaguchi Y, Shimauchi R, Nishibori N, Kawashima K, Oshitani S, Fujiya A, et al. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients. *J Diabetes Investig.* 19 juin 2018;

## SERMENT

- *En présence des Maîtres de cette école, de mes chers condisciples et devant l'effigie d'Hippocrate, je promets et je jure, au nom de l'Être suprême, d'être fidèle aux lois de l'honneur et de la probité dans l'exercice de la médecine.*
- *Je donnerai mes soins gratuits à l'indigent et n'exigerai jamais un salaire au-dessus de mon travail.*
- *Admis (e) dans l'intérieur des maisons, mes yeux ne verront pas ce qui s'y passe, ma langue taira les secrets qui me seront confiés, et mon état ne servira pas à corrompre les mœurs, ni à favoriser le crime.*
- *Respectueux (se) et reconnaissant (e) envers mes Maîtres, je rendrai à leurs enfants l'instruction que j'ai reçue de leurs pères.*
- *Que les hommes m'accordent leur estime si je suis fidèle à mes promesses. Que je sois couvert (e) d'opprobre et méprisé (e) de mes confrères si j'y manque.*

## ABSTRACT

### ABSTRACT

**Background :** Bullous pemphigoid (BP) is the most frequent autoimmune bullous disease and a set of 4 clinical criteria highly consistent with BP diagnosis has been previously validated. However, clinical spectrum of diseases may change over time and recently a number of unusual clinical features seem to have emerged in some BP patients. Accordingly a retrospective study was designed to reappraise the validity of the aforementioned criteria over time in a large cohort of well-documented BP in this setting of a possibly increasing frequency of atypical features and to describe possible new clinical patterns of BP and their potential time-related occurrence over the last two decades.

**Patients and methods :** Well-documented BP patients diagnosed between January 2001 and April 2017 were included in this retrospective analysis. The following data were collected : baseline characteristics of patients, extent of the disease, distribution and type of cutaneous lesions, presence of mucous lesions, presence of at least one atypical clinical (topographical or lesional) feature, presence or absence of at least 3 of the prior validated diagnostic clinical criteria. In order to identify a possible time-related shift of clinical features, data from 4 chronological groups of 4 years (G1 to G4) were statistically compared.

**Results :** 312 patients were included and analyzed. At least 3 of the 4 classical criteria were present in 278 patients (89.1%), but with a trend toward a steady decrease of relevance over time (G1 93.0% vs G4 83.8%,  $p$  0.067). The most frequent missing criteria were absence of mucosal involvement followed by absence of head and neck involvement. 206 patients (66.0%) displayed at least one atypical clinical feature and chronological analysis confirmed a significant time-related increase of atypical pattern frequency (G1 57.9%, G4 73.7%,  $p$  0.041). Head and neck, palmoplantar, mucosae involvement were observed in 56 (17.9%), 151 (48.4%) and 58 (18.6%) patients respectively, with an upward, although non significant trend between G1 and G4 ( $p$  0.071,  $p$  0.088,  $p$  0.094 for these 3 items respectively).

**Discussion :** Clinical presentation of BP seems to have evolved over time with a progressively higher proportion of atypical topographical and/or lesional characteristics, mainly regarding mucous membrane, head and neck and palmo-plantar involvement. This shift probably underlies the progressive reduction of the percentage of BP patients fulfilling at least 3 of the 4 BP previously validated diagnostic criteria even though these criteria remain robust in our study. Environmental causes, mainly drugs might affect clinical presentation of BP since a higher frequency of mucosal lesions has been recently reported in dipeptidyl peptidase 4 inhibitors (DPP4is)-induced BP compared to other BP patients.

**Key words:** bullous pemphigoid, atypical presentation, clinical patterns